中国血液净化

›› 2008, Vol. 7 ›› Issue (8): 407-409.

• 论著 •    下一篇

缬沙坦对维持性血液透析患者促红细胞生成素疗效的影响

刘雪梅 刘子栋 王 丽 刘孝宏 靖永胜 朱 斌 王小平   

  1. 250001 1山东中医药大学第二附属医院肾内科；250013 2济南市中心医院友谊肾脏病/血液净化中心
  • 收稿日期:2008-02-06 修回日期:1900-01-01 出版日期:2008-08-12 发布日期:2008-08-12

The effect of Valsartan on erythropoietin in the treatment of maintenance hemodialysis patients

LIU Xue-mei, LIU Zi-dong, WANG li,, LIU Xiao-hong, JING Yong-sheng, ZHU Bin, WANG Xiao-ping   

  1. 1Department of Nephrology, The Second Affiliated Hospital of Shandong Traditional Medicine University, Ji抧an 250001, China; 2Friendship Center for Kidney Diseases and Blood Purification, Ji抧an Central Hospital, Ji抧an 250013, China
  • Received:2008-02-06 Revised:1900-01-01 Online:2008-08-12 Published:2008-08-12

RichHTML

0

PDF

234

摘要： 目的 探讨缬沙坦对血液透析患者促红细胞生成素(erythropoietin, EPO )疗效的影响。方法 选择维持性血液透析伴有高血压的患者共55人，其中长期接受EPO治疗者40人随机分为A、B组；不接受EPO治疗及输血患者15人随机分为C、D组。A、C两组接受缬沙坦治疗；B、D两组作为对照。观察治疗前后患者Hb、Hct、EPO水平的变化，采用随机对照的方法进行前瞻性研究。结果 A、B、D三组患者治疗前后Hb、Hct、EPO水平无显著性差异，C组患者治疗后Hb、EPO浓度明显降低。A组缬沙坦平均用药剂量大的11例患者治疗后Hb下降。结论 缬沙坦可能通过抑制内源性EPO的产生而加重贫血；小剂量缬沙坦一般不影响外源性EPO的疗效，而大剂量的缬沙坦对外源性EPO的疗效可能有一定的影响。

关键词: 缬沙坦 促红细胞生成素 血液透析 贫血

Abstract: Objective To investigate Valsartan on the effect of erythropoietin (EPO) in the treatment of maintenance hemodialysis patients with anemia. Methods A total of 55 patients undergoing hemodialysis with stable clinical conditions and a hemoglobin level of 70-100g/L were enrolled in this study. They were assigned into 4 groups. Patients in groups A (n=20) and B (n=20) received EPO therapy, and those in groups C (n=8) and D (n=7) without the EPO therapy. In addition, patients in groups A and C were treated with Valsartan, and those in groups B and D with Amlodipine. Hb, hematocrit (Hct), and EPO levels were measured before and after the therapy. Results In groups A, B and D, no significant differences were found in the average Hb, Hct and EPO levels before and after the treatment for 6 months. In group C, however, Hb and EPO levels were significantly decreased after the treatment for 6 months. In group A, the decrease of Hb after the treatment was found in the 11 patients receiving higher dose of Valsartan. Conclusions Valsartan may cause the inhibition of endogenous EPO in hemodialysis patients. Lower dose of Valsartan does not alter the effect of exogenous EPO, but higher dose of Valsartan reduces the therapeutic effect of exogenous EPO in hemodialysis patients with anemia.

Key words: Erythropoietin, Hemodialysis, Anemia

中图分类号: